Clinical trial NCT00002015: An Open Label Evaluation of the Safety and Pharmacokinetics of Ganciclovir in Children
Official title: An Open Label Evaluation of the Safety and Pharmacokinetics of Ganciclovir in Children
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Cytomegalovirus Retinitis
HIV Infections
Keywords: Retinitis
Ganciclovir
Cytomegalovirus Infections
Acquired Immunodeficiency Syndrome
Immunocompromised Host
Lead sponsor: NIH AIDS Clinical Trials Information Service
Sponsor class: INDUSTRY
First posted: 2001-08-31
Enrollment: 20
Sex: ALL
Minimum age (years): 3
Maximum age (years): 12
Standard ages: CHILD
Accepts healthy volunteers: no
Primary purpose: TREATMENT

Brief summary: To evaluate the pharmacokinetics of intravenous ganciclovir in children (ages 3 months - 12 years). To determine the safety and tolerance of a 2 to 3 week induction course of ganciclovir IV in immunocompromised children receiving treatment for life- or sight-threatening cytomegalovirus infections.


Eligibility criteria: Inclusion Criteria

Concurrent Medication:

Allowed:

* Topical acyclovir.
* Consult with the Syntex study monitor for the following:
* Cytokines.
* Soluble CD4.
* Trichosanthin (Compound Q).
* Imipenem-cilastatin.
* Other investigational drugs.

Patients must have the following:

* Congenital or acquired immune deficiency.
* Eligibility to receive ganciclovir for the treatment of life- or sight-threatening Cytomegalovirus (CMV) disease.

Exclusion Criteria

Co-existing Condition:

Patients with the following conditions or symptoms are excluded:

* Mild to moderate Cytomegalovirus infection that does not satisfy the clinical severity criteria.
* Congenital or neonatal CMV infections without documented congenital or acquired immunodeficiency.

Concurrent Medication:

Excluded:

* Other myelosuppressive drugs.
* Antimetabolites.
* Alkylating agents.
* Nucleoside analogs (topical acyclovir is allowed).
* Interferons.
* Foscarnet.
* Consult with the Syntex study monitor for the following:
* Cytokines.
* Soluble CD4.
* Trichosanthin (Compound Q).
* Imipenem-cilastatin.
* Other investigational drugs.

Patients with the following are excluded:

* Mild to moderate Cytomegalovirus (CMV) infection that does not meet the clinical severity criteria.
* Absolute neutrophil count (ANC) \< 500 cells/mm3 or a platelet count \< 25000 platelets/mm3. Note:
* Exceptions may be made for patients with pre-existing neutropenia or thrombocytopenia and immediately life-threatening disease, if the investigator believes that a delay in starting ganciclovir therapy is not advisable. In such patients, the investigator should advise the parents or guardians of the risk of further bone marrow suppression and the increased risk of infection or bleeding.
* Receiving excluded medications that it is not possible to discontinue.
* Congenital or neonatal CMV infections without documented congenital or acquired immunodeficiency.
* Demonstrated hypersensitivity to acyclovir or ganciclovir.

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
city: Birmingham
country: United States
facility: Univ of Alabama at Birmingham
state: Alabama
city: Los Angeles
country: United States
facility: Children's Hosp of Los Angeles
state: California
city: Los Angeles
country: United States
facility: Los Angeles County - USC Med Ctr
state: California
city: Los Angeles
country: United States
facility: Ctr for the Health Sciences / UCLA Med Ctr
state: California
city: Chicago
country: United States
facility: Univ of Chicago / Wylers
state: Illinois
city: Omaha
country: United States
facility: Univ of Nebraska Med Ctr
state: Nebraska
city: Rochester
country: United States
facility: Univ of Rochester Med Ctr
state: New York
city: Houston
country: United States
facility: Baylor College of Medicine / Texas Children's Hosp
state: Texas
Study officials:
References: